Cargando…
A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease
Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects six to seven million people in Latin America. Lately, it has become an emerging public health concern in nonendemic regions such as North America and Europe. There is no prophylactic or therapeutic vaccine as yet,...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430786/ https://www.ncbi.nlm.nih.gov/pubmed/30911415 http://dx.doi.org/10.1038/s41541-019-0107-7 |